Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology

The patent allowance advances intellectual-property protection, but does not constitute regulatory approval or establish safety or efficacy.

Rhea-AI Summary

Hydreight Technologies (HYDTF) announced that investment partner Insu Therapeutics received a U.S. patent allowance covering its buccal peptide-delivery technology.

The Notice of Allowance supports technology behind InsuTab, an investigational insulin formulation, and BuccaGLP, an investigational semaglutide formulation. Both are being developed to deliver medicines through the mouth's lining. Hydreight previously completed a C$300,000 investment in Insu and obtained U.S. distribution rights for peptide medicines incorporating the technology. Insu holds an exclusive worldwide technology licence from the University of British Columbia. Final issued claims will determine patent protection. Hydreight's distribution opportunity depends on successful development and regulatory approvals; any introduction would also require product-specific prescribing, pharmacy and operational arrangements.

Positive

• Minor pointU.S. patent allowance advances the technology underlying Hydreight's investment and potential distribution opportunity.
• Minor pointC$300,000 investment completed previously gave Hydreight exposure to Insu and U.S. distribution rights for technology-based peptide medicines.
• Minor pointInsu's exclusive worldwide UBC licence supports the technology underlying Hydreight's potential distribution opportunity.
• Minor pointCompleted laboratory, cell-culture and rat studies provide proof-of-concept work for Insu's buccal insulin program.

Negative

• Minor pointHydreight's distribution opportunity remains subject to successful development and regulatory approvals.
• Minor point. Forward-looking: it has not happened yet and may not happen.Product-specific prescribing, pharmacy and operational arrangements would be required for any future U.S. introduction.
• Minor point. Forward-looking: it has not happened yet and may not happen.Final issued patent claims will determine the scope of protection following the allowance.

Key Figures

Investment in Insu: C$300,000

Investment in Insu

C$300,000

Completed March 13, 2026; associated with previously disclosed U.S. distribution rights

Key Terms

notice of allowance, buccal, glp-1, mucoadhesive

4 terms

notice of allowance regulatory

"received a Notice of Allowance from the United States Patent and Trademark Office"

A notice of allowance is an official confirmation from a patent office that a patent application has met all necessary requirements and is approved for granting. It signals that the invention is likely to receive legal protection soon, which can be important for investors considering the value and exclusivity of a new product or technology. Think of it as a green light indicating that the invention is on track to become legally protected.

buccal medical

"its buccal peptide-delivery technology"

Buccal describes a route of drug administration where a medicine is placed against the inner lining of the cheek so the active ingredient is absorbed through the oral mucosa. Absorption across the cheek tissue can produce either local effects or direct entry into the bloodstream, often giving faster onset than swallowing and avoiding some degradation in the stomach and first-pass liver metabolism; it is distinct from sublingual administration, which targets the tissue under the tongue.

glp-1 medical

"its investigational buccal semaglutide formulation"

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

mucoadhesive technical

"the platform's mucoadhesive, layered dosage-form architecture"

Mucoadhesive describes a material or drug formulation that sticks to mucous membranes—surfaces like the inside of the mouth, nose, throat or gut—to stay in place longer and release medicine locally or more steadily. For investors, mucoadhesive properties can improve a product's effectiveness, dosing convenience and competitive differentiation, influencing clinical success, regulatory review and commercial value much like a bandage that holds medicine against a wound for longer, increasing its benefit.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Milestone advances the technology behind Hydreight's strategic investment and previously announced U.S. distribution rights

VANCOUVER, BC and LAS VEGAS, Oct. 8, 2026 /PRNewswire/ -- Hydreight Technologies Inc. ("Hydreight" or the "Company") (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6) today announced that Insu Therapeutics Inc. ("Insu"), in which Hydreight holds a strategic investment, has received a Notice of Allowance from the United States Patent and Trademark Office ("USPTO") for a patent application covering its buccal peptide-delivery technology.

The allowance advances the intellectual-property foundation supporting InsuTab™, Insu's investigational buccal insulin formulation, and BuccaGLP™, its investigational buccal semaglutide formulation. Both programs are being developed to deliver peptide medicines through the lining of the mouth, providing a potential needle-free alternative to injections.

As disclosed in its March 13, 2026 news release, Hydreight completed a C$300,000 investment in Insu and obtained distribution rights for U.S. distribution of peptide medicines incorporating Insu's buccal technology. These distribution rights do not limit Insu and Hydreight ability to pursue licensing, development, commercialization or other strategic partnerships with large pharmaceutical The patent allowance further strengthens the value of Hydreight's strategic investment and its potential future U.S. distribution opportunity, while supporting Insu's broader global development, licensing and commercialization strategy

Connecting delivery innovation with U.S. healthcare infrastructure

"This milestone advances the technology behind our investment in Insu and the potential distribution opportunity we have secured in the United States," said Shane Madden, Chief Executive Officer of Hydreight. "Our focus is to connect innovations in therapeutic delivery with the infrastructure needed to reach patients. Insu's development programs give us an opportunity to participate in that process as the technology progresses."

Hydreight's platform connects healthcare providers, pharmacies and patients across all 50 U.S. states. Its VSDHOne platform supports businesses delivering physician-supervised healthcare through virtual and direct-to-consumer channels.

If Insu's candidates successfully complete development and receive the required approvals, Hydreight could use its healthcare infrastructure to support U.S. distribution under its previously disclosed rights. Any future introduction would require appropriate product-specific prescribing, pharmacy and operational arrangements.

Exclusive technology licence and U.S. patent allowance

The Notice of Allowance relates to U.S. Patent Application No. 18/513,373, titled "Mucoadhesive Pharmaceutical Dosage Form for Unidirectional Release of Peptide Therapeutic Particles."

Insu holds an exclusive, worldwide licence from the University of British Columbia ("UBC"), granting it rights to develop, market, commercialize and sublicense the licensed technology globally.

The allowed claims relate to the platform's mucoadhesive, layered dosage-form architecture and unidirectional release mechanism for insulin and GLP-1 therapeutics. The published application identifies semaglutide, liraglutide, dulaglutide and exenatide, alongside multiple insulin analogues. The scope of protection will be determined by the final issued claims.

A different route for delivering peptide medicines

Insu's technology uses a layered dosage form designed to adhere to the inner cheek and direct the release of an encapsulated peptide toward the underlying tissue. The approach is intended to support absorption through the mouth's lining rather than relying on gastrointestinal absorption after swallowing.

Insu reports that its formulation does not require fasting or restrictions on food and drink before or after dosing. The buccal format also avoids the needles and associated injection supplies required to administer an injectable product. Further studies are required to establish the performance, safety and efficacy of the individual candidates.

Insu has completed laboratory, cell-culture and rat studies at UBC as proof-of-concept work for its buccal insulin program. Its buccal semaglutide program applies the same delivery architecture to a GLP-1 medicine used in metabolic disease.

Research by members of the Insu scientific team was published in Pharmaceutics in September 2023 under the title "Concept for a Unidirectional Release Mucoadhesive Buccal Tablet for Oral Delivery of Antidiabetic Peptide Drugs Such as Insulin, Glucagon-like Peptide 1 (GLP-1), and their Analogs." The publication provides scientific context for Insu's development approach.

"This allowance advances an important part of our development strategy," said Dr.Anubhav Pratap-Singh, Board chair and Co-Founder of Insu Therapeutics. "We are bringing together exclusive technology rights, formulation research and a clear initial focus on insulin and semaglutide. Our objective is to translate that foundation into practical needle-free treatment options and future commercial opportunities."

InsuTab™ and BuccaGLP™ remain investigational and are not approved for commercial sale. The patent allowance relates to intellectual property protection and does not constitute regulatory approval or establish the candidates' safety or efficacy. Hydreight's distribution opportunity remains subject to successful development and regulatory approvals.

On behalf of the Board of Directors

Shane Madden
Director and Chief Executive Officer
Hydreight Technologies Inc.

About Insu Therapeutics

Insu Therapeutics Inc. is a Vancouver-based biotechnology company and UBC spin-off developing needle-free buccal formulations for peptide medicines. Its initial programs are InsuTab, a buccal insulin formulation, and BuccaGLP, a buccal semaglutide formulation. Insu holds an exclusive worldwide licence from UBC to its mucoadhesive, unidirectional peptide-delivery technology, with related patent applications in the United States, Canada, Europe and Japan.

About Hydreight Technologies Inc.

Hydreight Technologies Inc. is a U.S.-focused digital health infrastructure company providing technology, healthcare provider, pharmacy and compliance solutions across the United States.

Its proprietary, fully integrated platform supports a network of more than 3,000 nurses, more than 300 independent doctors and pharmacy relationships across all 50 states. The platform includes a built-in suite of integrated tools for accounting, documentation, sales, inventory, booking and managing patient data, which enables licensed healthcare professionals to provide services directly to patients at home, office or hotel.

Hydreight bridges the gap between provider compliance and patient convenience, supporting nurses, med spa technicians and other licensed healthcare professionals. The Hydreight platform allows healthcare professionals to deliver services independently or add mobile services to existing location-based operations.

Hydreight has relationships with pharmacy providers servicing all 50 states and is closely affiliated with a U.S. certified e-script and telemedicine provider network.

For more information, visit www.hydreight.com.

About VSDHOne – Direct-to-Consumer Platform

Developed in partnership with Victory Square Technologies (CSE: VST) (OTC: VSQTF) (FWB: 6F6), Hydreight Technologies launched the VSDHOne platform.

VSDHOne aims to simplify the challenges for companies and medi-spa businesses seeking to enter the online healthcare space compliantly. The platform is designed to help businesses launch direct-to-consumer healthcare brands across all 50 states.

Offerings include GLP-1s, peptides, personalized healthcare treatments, sermorelin, testosterone replacement therapy ("TRT"), hair loss, skincare, sexual health and other healthcare categories.

Hydreight has invested in technology, legal and infrastructure to launch the platform. VSDHOne provides a modular, end-to-end solution for businesses looking to launch direct-to-consumer healthcare brands, including compliance and telemedicine technology and access to nationwide doctor and pharmacy networks.

Reference

Pratap-Singh A., Guo Y., Baldelli A. and Singh A. Pharmaceutics. 2023;15(9):2265. DOI: 10.3390/pharmaceutics15092265.

Forward-Looking Information

This release contains forward-looking information concerning anticipated patent issuance and scope, Insu's development programs, potential product benefits, regulatory approvals, commercialization and Hydreight's potential future distribution of products utilizing Insu's technology. Such information reflects current expectations and assumptions, including that Insu can obtain sufficient funding, generate satisfactory development results, secure required approvals and maintain the relevant intellectual-property and contractual rights, and that suitable manufacturing and distribution arrangements can be established. Forward-looking information is subject to risks and uncertainties, including patent issuance and scope, development outcomes, safety and efficacy findings, funding availability, regulatory requirements, manufacturing capacity, competition, market adoption and the ability to implement commercial arrangements. Actual results may differ materially. There is no assurance that Insu's candidates will receive regulatory approval or that Hydreight will generate revenue from its distribution rights. Readers should also review the risk factors in the Company's filings on SEDAR+. Except as required by applicable law, the Company undertakes no obligation to update forward-looking information.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/hydreight-highlights-us-patent-allowance-for-insu-therapeutics-needle-free-insulin-and-glp-1-delivery-technology-302902230.html

SOURCE Hydreight Technologies Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Insu's U.S. patent allowance mean for Hydreight?

The allowance advances the intellectual-property foundation behind technology in which Hydreight invested and for which it holds U.S. distribution rights. It covers a layered dosage form that adheres to the mouth's lining and releases peptide medicines in one direction. It does not constitute regulatory approval or establish safety or efficacy.

How much did Hydreight invest in Insu, and what rights did it obtain?

Hydreight completed a C$300,000 investment in Insu and obtained U.S. distribution rights for peptide medicines incorporating Insu's buccal technology. Those rights were previously disclosed in March 2026.

Do Hydreight's Insu distribution rights restrict other pharmaceutical partnerships?

The distribution rights do not limit Insu and Hydreight's ability to pursue licensing, development, commercialization or other partnerships with large pharmaceutical companies.